OCGN - Ocugen, Inc.
IEX Last Trade
0.8265
-0.016 -1.948%
Share volume: 5,455
Last Updated: Fri 27 Dec 2024 04:29:55 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.12%
PREVIOUS CLOSE
CHG
CHG%
$0.84
-0.02
-1.91%
Fundamental analysis
26%
Profitability
35%
Dept financing
19%
Liquidity
42%
Performance
15%
Performance
5 Days
-2.96%
1 Month
-20.96%
3 Months
-27.12%
6 Months
-43.89%
1 Year
38.38%
2 Year
-35.30%
Key data
Stock price
$0.83
DAY RANGE
$0.79 - $0.87
52 WEEK RANGE
$0.52 - $2.10
52 WEEK CHANGE
$27.18
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Shankar Musunuri
Region: US
Website: ocugen.com
Employees: 80
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: ocugen.com
Employees: 80
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis. OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD) and OCU200, is in preclinical development stage.
Recent news